Alzheimer’s, a form of dementia that affects a patient’s behavior, thinking, and memory, is a sluggish-progressing disorder that gradually deteriorates neurons associated with the gaining knowledge of part of the cerebrum. It is the most common and large form of dementia, affecting over 60% of humans aged 65 and above. However, with accelerated cognizance and developments in expertise the disease’s pathophysiology, numerous novels signaling pathways had been observed, leading to the evolution of diverse diagnostic tools that have revolutionized disease prognosis.
The global population is ageing unexpectedly, making Alzheimer’s disorder a significant fitness challenge. This has also created new growth possibilities inside the Alzheimer’s drug market place. As in keeping with the United Nations’ World Population Prospects, an envisioned 962 million human beings aged 60 or over are projected to grow at an annual rate of 3% and attain 1.4 billion by 2030. The geriatric population in Europe is the best (25% of the population). At the same time, Asia Pacific has a geriatric population of 547 million, expected to attain 900 million via 2025, making these regions potential growth markets. India alone reports over 1 million cases of Alzheimer’s disease yearly. North America has taken the lead in Alzheimer’s disease treatment, with an anticipated 5.5 million patients in 2017. The world’s superior healthcare infrastructure and early adoption of novel technologies have placed it as a sizeable marketplace for Alzheimer’s drug market.
The advent of latest inclined cloud-primarily based cognitive evaluation systems will assist pharmaceutical corporations in figuring out the effects of drugs on patients. This will enable pharmaceutical businesses to assess the cognitive pipeline drug efficacy and safety of the pipeline. For instance, Cambridge Cognition’s Cantab Connect product has been particularly evolved to measure the effectiveness of medicine for mild, mild, and prodromal AD. Adopting such era is anticipated to beautify the probabilities of product approvals, consequently riding the Alzheimer’s drug market.
Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=alzheimer-s-pipeline-drugs-review-alzheimer-s-disease-drug-market-and-forecast-global-analysis-131-p.php
Our comprehensive report identifies the dominant players in the market as Sanofi SA, F. Hoffmann-La Roche Ltd., Pfizer, Inc., Abbott Laboratories, Bayer, Merck & Co., Boehringer Ingelheim GmbH, GlaxoSmithKline Plc., Novartis, Eli Lilly and Company, and Teva Pharmaceuticals.
In January 2023, LEQEMBI, an amyloid beta-protein inhibitor jointly developed by Biogen and Eisai, received accelerated approval from the US FDA, the US FDA converted the accelerated approval to a traditional one after a confirmatory trial demonstrated a 27% slowing of decline. This breakthrough achievement addresses the unmet needs of patients with early Alzheimer’s and opens doors for other drugs that target the underlying disease pathology.
Market Summary
Product – Alzheimer’s Drug Market breakup from 5 viewpoints: Donepezil, Galantamine, Rivastigmine, Memantine, Others
End User – Alzheimer’s Drug Market breakup from 4 viewpoints: Hospitals, Clinics, Nursing homes, Homecare Centers
Region – Alzheimer’s Drug Market breakup from 4 Regions: North America, Europe, Asia-Pacific, Rest of the World
All key players have been covered from 3 viewpoints: Overview, Strategy, Financial Insight
Company Analysis:
1. Sanofi SA
2. F. Hoffmann-La Roche Ltd.
3. Pfizer, Inc.
4. Abbott Laboratories
5. Bayer
6. Merck & Co.
7. Boehringer Ingelheim GmbH
8. GlaxoSmithKline Plc.
9. Novartis
10. Eli Lilly and Company
11. Teva Pharmaceuticals
About the Company:
Renub Research is a Market Research and Consulting Company. We have more than 15 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.
Contact Us:
Renub Research
Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)
Email: info@renub.com
LinkedIn: https://in.linkedin.com/company/renub-research
Web: www.renub.com
